AgingResearch.NewsJoin free

IGFBP7 vaccine

IGFBP7 vaccine has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jul 11, 2024: “Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7”.

Intervention

1 paper studies it1 findingUpdated

More peptides

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: Japan Society for the Promotion of Science
  • 1 of 1 finding with company ties
  • Animals1

What did studies of IGFBP7 vaccine find?

1

Studies of IGFBP7 vaccine measured 1 outcome; the most studied are cardiac dysfunction (1 study).

Cardiac dysfunction

downin mice1

1 study

  1. IGFBP7 vaccine decreases cardiac dysfunction in mice.

    “EC-specific deletion of Igfbp7 and the vaccine targeting Igfbp7 ameliorated cardiac dysfunction with increased oxidative phosphorylation in cardiomyocytes under pressure overload.”

    Animalspressure overload

    Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7

    Circulation

Latest

Related